Project Grant R01HL169591

Award Date 8/15/24
Completion Date 7/31/28
Dollars Obligated $711K
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
St. Louis, MO 63110, USA
Similar Awards
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $195,846 to Washington University to investigate the role of blood-brain barrier disruption on ischemic brain injury and cognitive impairment in sickle cell disease (SCD). The key objectives are to: 1) assess blood-brain barrier permeability in SCD patients compared to healthy controls, 2) examine thromboinflammatory pathways associated with blood-brain...
This Project Grant award of $1,995,664 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will fund a supplemental study to the Nutrition for Precision Health (NPH) trial. The study aims to determine dietary iron requirements in a representative sample of U.S. adults by quantifying iron losses and bioavailability from different diets. The data collected will...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), is funded under the Cardiovascular Diseases Research program (CFDA 93.837). The $213,284 award to the Rector & Visitors of the University of Virginia (UVA) supports research to decipher the molecular mechanisms by which systemic iron homeostasis regulates endothelial function and hemoglobin alpha (HBA) expression in the microvasculature. The central hypothesis...
This federal Project Grant award for $657,368.00, issued by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the mechanisms controlling microRNA (miRNA) processing and degradation pathways during hematopoietic development. The primary awardee, The Washington University, will utilize human pluripotent stem cell lines with mutations in miRNA deadenylases and exosome components to identify novel...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $1,152,592 to the University of California, Los Angeles (UCLA) to conduct research on the mechanisms by which iron deficiency worsens inflammatory tissue injury. The project aims to define the molecular pathways underlying the adverse interaction between iron deficiency and...
This Project Grant award of $1,005,081 from the National Institute on Aging (CFDA 93.866 - Aging Research) will support research to determine the degree to which understanding of healthy and pathological brain aging can be informed by early neurodevelopment. The key goals are to: 1) Quantify similarities and differences in the spatiotemporal progression of brain development and degeneration, 2) Determine the impact of deprivation and genetic risk on functional and structural brain development...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $633,720 to The Washington University to conduct research on protein arginylation and its impact on cardiovascular health and development. The key objectives are to: Develop a chemical proteomics platform to comprehensively identify proteins that undergo arginylation in cardiac cells and tissues. This will involve mapping the "arginylome" and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $154,796 to Vanderbilt University Medical Center to utilize non-invasive neuroimaging methods to investigate cerebral oxygen utilization in adults with sickle cell disease (SCD). The research aims to: 1) assess how treatment-induced increases in hemoglobin levels impact cerebral blood flow and arterial-to-venous transit times in SCD...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $225,000 to investigate the role of the protein α-synuclein in regulating the erythroid iron restriction response. The research aims to elucidate how α-synuclein and the neurotransmitter dopamine modulate erythropoiesis during iron deficiency, which can lead to iron deficiency anemia....
This Project Grant award, valued at $607,535, was provided by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate the effects of the breakdown product hemin on the pulmonary endothelium and its contribution to the pulmonary complications of sickle cell disease, including acute chest syndrome and pulmonary hypertension. The research aims to evaluate the specific effects of...

This Project Grant award in the amount of $710,899.00 was provided by the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), to The Washington University in St. Louis. The goal of this research project is to delineate the short and long-term neurocognitive impact of late-childhood iron deficiency anemia (IDA) in young females. Specifically, the project will evaluate cognitive function and brain structure/connectivity in 88 young females aged 12-21 with IDA, both at the time of diagnosis and after iron repletion therapy, and compare to 44 age-matched females without anemia. The research aims to determine the cerebral metabolic stress caused by late-childhood IDA, the reversibility of neurocognitive dysfunction with iron treatment, and the long-term impact on white matter integrity and cognitive abilities. The findings could have important implications for IDA screening and treatment recommendations during a critical developmental period for young women. The award period runs from August 15, 2024 to July 31, 2028.

Generated 7/1/25, 4:26 AM